To prepare for the gradual replacement of ReFacto with ReFacto AF on the market, the company that makes the medicine will provide educational packs for healthcare workers who will prescribe or use ReFacto AF, for all associations of haemophilia patients in the European Union (EU), for patients receiving ReFacto AF and for laboratories that will monitor patients receiving ReFacto AF.